Julia Binder

What motivates me is constant curiosity and commitment to enhancing the lives of both mothers and their babies.

Julia Binder, MD, PhD, is the Head of Fetal Medicine and Associate Professor at the Department of Obstetrics and fetomaternal Medicine at the Medical University of Vienna (MUV), Vienna, Austria.

Dr. Julia Binder is the Head of Fetal Medicine and an Associate Professor at the Department of Obstetrics and Fetomaternal Medicine at the Medical University of Vienna (MUV). She completed a fellowship in Fetal Medicine at St George’s Hospital in London in 2016, followed by a fellowship in Fetomaternal Medicine at MUV. In 2019, Dr. Binder earned her PhD in Endocrinology, Metabolism and Nutrition and completed her Habilitation in 2021 on angiogenic markers and maternal hemodynamic function in women with hypertensive disorders of pregnancy. She also leads the Preeclampsia Research Group and has published over 45 articles as a first and co-author. 

Her recent research, Prognostic Value of Angiogenic Markers in Pregnancy with Fetal Growth Restriction, introduces novel angiogenic markers that hold great promise in advancing the understanding and management of fetal growth restriction (FGR).

Advancing maternal-fetal medicine: The role of angiogenic markers in managing fetal growth restriction

Dr. Binder's research focuses on the management of pregnancies with fetal growth restriction (FGR) and the potential role of angiogenic markers in improving maternal and fetal health outcomes. Women carrying a fetus with FGR are often concerned about the possibility of developing preeclampsia, a condition characterized by high blood pressure during pregnancy along with organ damage such as proteinuria. Preeclampsia is known for its high rates of maternal and neonatal morbidity and mortality, making its early detection crucial.

Dr. Binder's study suggests that angiogenic markers should be used to guide the care of women carrying a growth-restricted fetus. These markers can help rule out the development of preeclampsia, providing much-needed reassurance to women already facing the stress of a complicated pregnancy.

The research introduces novel biomarkers that have the potential to advance the understanding and management of FGR. These markers offer a new perspective and open the door for further exploration in this critical area. Based on rigorous scientific methodology, the study presents robust evidence supporting the prognostic utility of angiogenic markers and offers significant implications for clinical practice. The findings have the potential to influence clinical guidelines and set a foundation for future research in maternal-fetal medicine. By validating a method for identifying and managing pregnancies at risk of FGR, the study addresses a pressing medical need and offers the possibility for improved maternal and neonatal outcomes.

Commitment to Improving Maternal and Fetal Health

Dr. Binder is motivated by her constant curiosity and her commitment to enhancing the lives of both mothers and their babies. She finds energy in spending quality time with friends and family, engaging in inspiring conversations, practicing yoga and enjoying the outdoors. From a young age, Dr. Binder has strived to become a doctor, driven by a desire to make a difference and lead a meaningful life. Helping others has always been a key priority for her and it continues to bring her great joy and fulfillment.